Omnicell’s (OMCL) “Buy” Rating Reaffirmed at Benchmark

Benchmark reissued their buy rating on shares of Omnicell (NASDAQ:OMCL) in a report released on Tuesday morning,Benzinga reports. The firm currently has a $62.00 price target on the stock.

Several other equities research analysts also recently commented on OMCL. Bank of America reduced their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. Barclays boosted their price target on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. raised their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Wells Fargo & Company cut their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Craig Hallum increased their price target on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Omnicell has an average rating of “Hold” and an average price target of $52.33.

Omnicell Price Performance

Omnicell stock opened at $43.85 on Tuesday. The business has a 50 day simple moving average of $44.64 and a 200 day simple moving average of $43.10. The company has a market capitalization of $2.03 billion, a PE ratio of -112.43, a price-to-earnings-growth ratio of 30.78 and a beta of 0.78. Omnicell has a one year low of $25.12 and a one year high of $55.74.

Insider Transactions at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.64% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of OMCL. Van ECK Associates Corp raised its position in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after acquiring an additional 315 shares during the last quarter. First Horizon Advisors Inc. increased its position in Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after purchasing an additional 355 shares during the period. Redmond Asset Management LLC raised its holdings in Omnicell by 0.3% during the 4th quarter. Redmond Asset Management LLC now owns 121,209 shares of the company’s stock worth $5,396,000 after purchasing an additional 371 shares during the last quarter. GAMMA Investing LLC lifted its position in Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the period. Finally, Curi RMB Capital LLC boosted its stake in shares of Omnicell by 0.7% in the 3rd quarter. Curi RMB Capital LLC now owns 88,815 shares of the company’s stock valued at $3,872,000 after purchasing an additional 651 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.